Abstract: Alzheimer's disease (AD) is a chronic neurodegenerative disease which pathogenesis has not been fully elucidated. Its main pathological features are intracellular formation of neurofibrillary tangles (NFTs) and senile plaques formed by deposition of external amyloid β-peptide (Aβ). The clinical manifestations of AD patients have a gradual decline in memory and a gradual loss of daily behavioral ability, eventually progressing to long-term memory deficits. The long-term nature of AD has caused enormous emotional and financial burdens on patients, families of patients, and even society as a whole. The possible pathogenic factors are also widely discussed, but the pathogenic factors that have been clearly identified are Aβ protein deposition, inflammatory response, mitochondrial dysfunction, oxidative stress damage, and abnormal phosphorylation of Tau protein. Starting from the pathogenesis of AD, with the corresponding pathological factors as the target, the development of drugs with new pharmacological activities is underway. This article mainly discusses some research progress in the treatment of AD in recent years, aiming to provide new strategies and directions for future drug development.

Key words: Alzheimer's disease, targeted therapy, research progress